IMV News and Press, IMV Inc. From 11/10/21

IMV (NASDAQ:IMV): Q3 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.04M (-55.6% Y/Y) misses by $0.02M. Press Release For further details see: IMV EPS misses by $0.01, misses on revenue

IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood cancers while preserving patients’ quality of life, today ann...

IMV (NASDAQ:IMV) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is -$0.12 (+7.7% Y/Y) and the consensus Revenue Estimate is $0.06M (-33.3% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 dow...

AEG, OTCQX:ALEAF, AMTX, AYRO, AZUL, BAM, BGRY, CAE, CELH, OTCQX:CRLBF, DCBO, OTCQX:EDVMF, GRWG, HUT, IMV, OTCPK:MKGAF, NICE, NVVE, OGN, PSFE, QSI, RSLS, RWLK, SBH, SPCB, SPH, STNG, STXS, THRY, TMDI, TPR, TXMD, UTZ, VNRX, WB, WIX, WWR, XNET, YETI For Seeking Alpha's full earnings season calend...

MVP-S treatment increased survivin-specific T and B cell tumor infiltration, further validating the MVP-S mechanism of action Immunogenic/inflamed tumors are more susceptible to treatment with MVP-S Potential mechanisms of primary resistance to treatment were identified ...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while preserving patients’ quality of life today announced that it will hold a conference call...

Poster presentations show that: DPX generates peptide-specific, T cell-based immune responses that are more robust and more persistent than conventional water-based formulations The dual-targeted immunotherapy DPX-SurMAGE elicits a robust and specific T cel...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recur...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts featuring two DPX-based immunotherapies have been accepted for virtual poster presentation at t...

The following slide deck was published by IMV Inc. in conjunction with this event. For further details see: IMV (IMV) presents at 2021 Wells Fargo Healthcare Virtual Conference